NFO period: 06^th December - 20^th December, 2024

Highlights of the NFO:

• Scheme type - An open ended equity scheme following pharma, healthcare and allied theme


• Investment objective - The objective of the scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. However, there is no assurance that the investment objective of the scheme will be achieved.


• Product suitability - This product is suitable for investors who are seeking wealth creation over long term to by investing predominantly in equity and equity related instruments of pharma, healthcare and allied companies.


• Minimum Application Amount - First investment is Rs.500/- and in multiples of Rs.1/- thereafter


• Plan/ Options available - Regular Plan & Direct Plan having Growth option and Income Distribution cum Capital Withdrawal (IDCW) option with Payout of Income Distribution cum Capital Withdrawal sub-option, Reinvestment of Income Distribution cum Capital Withdrawal sub-option and Transfer of Income Distribution cum Capital Withdrawal sub-option.


• Fund Manager - Mr. Nimesh Chandan, Mr. Sorbh Gupta and Mr. Siddharth Chaudhary


• Benchmark - BSE Healthcare Total Return Index (TRI)